CD5 chimeric antigen receptor for adoptive T cell therapy

a t cell and chimeric antigen technology, applied in the field of immunology, cell biology, molecular biology, medicine, can solve the problems of high risk of incurable relapse, low cure rate of adult t-all cases, and difficulty in using car t cells against t-cell malignancies, so as to improve t cell persistence and antitumor responses.
US10786549B2Active Publication Date: 2020-09-29BAYLOR COLLEGE OF MEDICINE
6 Cites 1 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
BAYLOR COLLEGE OF MEDICINE
Publication Date
2020-09-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a national phase application under 35 U.S.C. § 371 that claims priority to International Application No. PCT / US16 / 29014 filed Apr. 22, 2016 which claims priority to U.S. Provisional Patent Application Ser. No. 62 / 151,609, filed Apr. 23, 2015, all of which are incorporated by reference herein in their entirety.INCORPORATION OF SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing, named “Sequence_Listing.txt” (14,300 bytes), created Oct. 23, 2017, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety.TECHNICAL FIELD

[0003] The present disclosure concerns at least the fields of immunology, cell biology, molecular biology, and medicine, including cancer medicine.BACKGROUND

[0004] Acute Lymphoblastic Leukemia (ALL) is the most common cancer in pediatric patients. T-lineage Acute Lymphoblastic Leukemia (T-ALL) accounts for 15% of ALL cases in children and 20-25% in adults. Cure rates for a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More